Cationized IVIg as a potential substitute to IVIg for the treatment of experimental immune thrombocytopenia.

Publication Type:

Journal Article


Int Immunopharmacol, Volume 16, Issue 4, p.409-13 (2013)


Animals, Blood Platelets, Cations, Disease Models, Animal, Female, Immunoglobulins, Intravenous, Immunologic Factors, Isoelectric Point, Liver, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Weight, Platelet Count, Purpura, Thrombocytopenic, Idiopathic, Spleen, Tissue Distribution


<p>In this study, we evaluated the possibility of using cationized IVIg (cIVIg) instead of IVIg as a more effective therapy for the treatment of experimental immune thrombocytopenia in mice. The pharmacokinetics (PK) and biodistribution of cIVIg and IVIg in mice were compared. cIVIg displayed a shorter plasma half-life and an increased organ uptake in both the spleen and liver compared to IVIg, suggesting that cIVIg could be more potent than IVIg to prevent platelet clearance in a mouse model of thrombocytopenia. However, although the biodistribution of cIVIg in the spleen and liver was improved, its ability to prevent platelet clearance in mice remained similar to that of IVIg. Altogether, our data demonstrate the possibility of using chemical cationization of IVIg preparations to increase organ uptake, and also highlight the challenges of developing effective substitutes to IVIg.</p>

Funding / Support / Partners

logo FRQ-S logo ctrn logo fci logo cihr irsc logo nserc logo MESISentinelle nord